FIRST GENERATION VERSUS NEWER GENERATIONS DRUG-ELUTING STENTS IN CHRONIC TOTAL OCCLUSION INTERVENTION

• Amro Elnagar, 
• Seung–Woon Rha, 
• Byoung Geol Choi, 
• sung il Im, 
• Sunwon Kim, 
• Jin Oh Na, 
• Seongwoo Han,
• Cheol Ung Choi, 
• Hong Euy Lim, 
• Jin Won Kim, 
• Eung Ju Kim, 
• Hong–Seog Seo, 
• Chang Gyu Park, 
• Dong Joo Oh

• Cardiovascular Center, Korea University Guro Hospital, Seoul, South Korea

Background

Successful revascularization of chronic total occlusions (CTOs) remains one of the most difficult challenges for interventional cardiologists. Despite of improved long–term outcomes by drug–eluting stents (DES), however, there are limited data regarding outcomes of different DESs following CTO intervention.

Methods

A total 201 patients (pts) who underwent percutanous coronary intervention (PCI) with DESs for CTOs lesions were enrolled. We compared the angiographic and clinical outcomes of first generation DES [Paclitaxel–eluting stents (Taxus™) and Sirolimus–eluting stents (Cypher™)] to newer generation DESs [Zotarolimus–eluting stents (Endeavor Resolute™) and Everolimus–eluting stents (Promus Element™ or Xience™).

Results

Baseline clinical characteristics were similar between the two groups except that first generations DESs group had more smokers and dyslipidemia. At index procedure, first generation DESs showed a trend towards longer lesion length, more fluoroscopy time and higher amount of contrast. However, angiographic follow up at six months, there were no significant differences between the two groups. Similar results were found at twelve months clinical follow up (Table).

Conclusions

In the current study, there were no significant differences between first and newer generations DESs at 6 months angiographic & 12 months clinical outcomes following successful CTOs intervention.

Copyright © 2012 Published by Elsevier Inc. All rights reserved.